Eversense CGM for Diabetes
(NA-PAS Trial)
What You Need to Know Before You Apply
What is the purpose of this trial?
This study is evaluating whether a continuous glucose monitor may help people with diabetes better manage their blood sugar.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It seems focused on comparing two methods of monitoring blood sugar, so you may not need to change your medications, but it's best to confirm with the trial organizers.
Is the Eversense CGM System safe for use in humans?
How is the Eversense CGM System different from other diabetes treatments?
What data supports the effectiveness of the Eversense CGM System treatment for diabetes?
Are You a Good Fit for This Trial?
Adults with Type 1 or Type 2 diabetes who have never used a continuous glucose monitor (CGM) for more than one week in the last six months. Participants must own an internet-enabled smartphone and be able to follow study instructions. Critically ill patients, those on dialysis, pregnant or nursing women, and individuals with certain medical conditions are excluded.Inclusion Criteria
Exclusion Criteria
Timeline for a Trial Participant
Screening
Participants are screened for eligibility to participate in the trial
Baseline
Participants manage their diabetes using self-monitoring of blood glucose (SMBG) for 6 months
Non-adjunctive CGM Use
Participants use the Eversense CGM System non-adjunctively for 6 months
Follow-up
Participants are monitored for safety and effectiveness after treatment
What Are the Treatments Tested in This Trial?
Interventions
- Blood glucose meter
- Eversense CGM System
Eversense CGM System is already approved in United States, European Union for the following indications:
- Continually measuring glucose levels in adults (age 18 and older) with diabetes for up to 90 days
- Continually measuring glucose levels in adults (age 18 and older) with diabetes for up to 180 days
Find a Clinic Near You
Who Is Running the Clinical Trial?
Senseonics, Inc.
Lead Sponsor